RT info:eu-repo/semantics/article
T1 Olive pomace phenolic compounds: from an agro-industrial by-product to a promising ocular surface protection for dry eye disease
A1 Katsinas, Nicolaos
A1 Gehlsen, Uta
A1 García Posadas, Laura
A1 Rodríguez Rojo, Soraya
A1 Steven, Philipp
A1 González García, María Jesús
A1 Enriquez De Salamanca Aladro, Amalia
K1 Ojo - Enfermedades y defectos - Tratamiento
K1 Síndrome de ojo seco
K1 Aceite de oliva
K1 Aceite de oliva - Análisis
K1 Olive pomace
K1 Phenolic extracts
K1 3201.09 Oftalmología
AB Dry eye (DED) is a prevalent disease with immune-mediated inflammation as the principal pathophysiological etiology. Olive pomace, the major by-product of the olive oil industry, is rich in high-value polyphenols. Their anti-inflammatory and immunomodulatory activities were determined on human CD4+ T cells (hTCD4+) and in a DED animal model. The viability of hTCD4+ cells isolated from peripheral blood and activated with phytohemagglutinin-M was evaluated after treatment for 48 h with an olive pomace extract (OPT3, 0.10–0.40 mg/mL) and its major compound, hydroxytyrosol (25–100 μM). Regarding the DED animal model, 100 μM hydroxytyrosol, 0.20 mg/mL OPT3, or vehicle (borate buffer) were topically administered to 14 days-desiccating stress-exposed (constant airflow/scopolamine administration) C57BL/6 mice. Tear volume, corneal fluorescein staining (CFS), CD4+, and CD8+ T cell count in lymph nodes (flow cytometry), and IP-10 and TNF-α gene expression (qRT-PCR) in the cornea, conjunctiva, and lacrimal glands were evaluated. OPT3 (0.2–0.4 mg/mL) and hydroxytyrosol (100 μM) significantly reduced hTCD4+ proliferation. In mice, both treatments reduced lacrimal gland IP-10 gene expression. OPT3 also decreased CFS, and conjunctival IP-10 and corneal TNF-α gene expression. In lymph nodes, hydroxytyrosol reduced CD3+, OPT3, and CD8+ count. Thus, a high-value application as a promising DED protection was proposed for olive pomace.
PB MDPI
SN 2077-0383
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/55602
UL https://uvadoc.uva.es/handle/10324/55602
LA eng
NO Journal of Clinical Medicine, 2022, Vol. 11, Nº. 16, 17 pp.
NO Producción Científica
DS UVaDOC
RD 17-jul-2024